Creatinine Elevation with Coversyl Plus

Mechanism and Risk Factors

Perindopril, as an ACE inhibitor, causes efferent arteriolar vasodilation, which reduces glomerular filtration pressure and can lead to an initial rise in serum creatinine, considered physiological and reflecting the drug's mechanism of action rather than nephrotoxicity in most cases, according to the American Heart Association 1, 2
A 10-20% increase in serum creatinine is commonly observed and expected after initiating ACE inhibitor therapy, as reported by the American College of Cardiology 1, 2
Indapamide, the diuretic component, can potentiate this effect through volume depletion, especially when used at higher doses, as noted by the American Society of Nephrology 2, 3
Pre-existing renal insufficiency increases the risk of more pronounced creatinine elevation, as stated by the National Kidney Foundation 1, 2
Concomitant use of NSAIDs or other nephrotoxic medications increases the risk of significant creatinine elevation, according to the American College of Rheumatology 1, 4

A rise in serum creatinine up to 30% from baseline is generally acceptable and not an indication to discontinue therapy, as recommended by the American Heart Association 2
Signs of acute kidney injury, such as oliguria, are a concern and require immediate attention, as advised by the American Society of Nephrology 1
Temporary discontinuation of Coversyl Plus may be advised during episodes of acute illness that could lead to dehydration, as suggested by the International Society of Nephrology 6
Counsel patients to temporarily hold Coversyl Plus during "sick days" with vomiting, diarrhea, or fever to prevent acute kidney injury, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 6

In the ADVANCE trial, which used perindopril-indapamide, acute increases in serum creatinine were associated with higher risk of adverse outcomes, but continuation of therapy still provided net benefit regardless of initial creatinine rise, as reported by the American Diabetes Association 5